Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation

More »
Recent News
DateTitle 
05/16/19
Announces resignation of Chief Medical Officer effective August 31, 2019 SOUTH SAN FRANCISCO, Calif. , May 16, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium
05/07/19
TAVALISSE® net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million, including $4.6 million from collaborations Opened clinical trial sites for Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); expect to enroll
04/30/19
SOUTH SAN FRANCISCO, Calif. , April 30, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on Tuesday, May 7 , 2019.  Rigel senior management will follow the announcement with a live

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site